Imunon (IMNN) AGM 2026 summary

Opening remarks and agenda

• The meeting was opened with a welcome to shareholders and an overview of the virtual format and agenda, with participation limited to shareholders of record as of April 17, 2026.

• Forward-looking statements and associated risks were highlighted, referencing SEC filings for further details.

• Time was allocated for shareholder questions at the end of the meeting.

Board and executive committee updates

• Directors and executive officers were introduced, including the CEO, CFO, CMO, and Corporate Secretary.

• The independent public accountant from WithumSmith+Brown was present.

Financial performance review

• Multiple financings were executed in the past year, including a May 2025 private placement ($3.25M), a December 2025 direct offering ($7M), and a June 2026 flexible financing (up to $10M).

• The company emphasized rigorous expense management and a focus on funding key clinical milestones.

• The financial strategy aims to extend the cash runway and support clinical program advancement.